Compare SSBI & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSBI | INKT |
|---|---|---|
| Founded | 1982 | 2017 |
| Country | United States | United States |
| Employees | 106 | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.7M | 70.6M |
| IPO Year | N/A | 2021 |
| Metric | SSBI | INKT |
|---|---|---|
| Price | $13.67 | $12.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 4.1K | ★ 60.1K |
| Earning Date | 05-01-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.60 | $6.66 |
| 52 Week High | $14.00 | $76.00 |
| Indicator | SSBI | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 57.47 | 52.14 |
| Support Level | $12.78 | $10.94 |
| Resistance Level | $13.68 | $12.58 |
| Average True Range (ATR) | 0.19 | 1.14 |
| MACD | 0.01 | 0.18 |
| Stochastic Oscillator | 87.51 | 37.18 |
Summit State Bank provides various banking products and services to individuals and businesses in Sonoma County, California. It offers personal and business checking, money market, sweep, savings, and demand accounts; time certificates of deposit; and specialized deposit accounts, such as professional, small business packaged, tiered, and retirement plan accounts. The company also provides loans, including commercial loans and leases; lines of credit; commercial real estate, small business administration, residential mortgage, and construction loans; home equity lines of credit; and term and equipment loans, as well as loans to agriculture-related businesses.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.